{
    "organizations": [],
    "uuid": "a62f84925af3b2274140e6e7298fbead220bb04f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-abbvie-says-upadacitinib-met-all-p/brief-abbvie-says-upadacitinib-met-all-primary-and-ranked-secondary-endpoints-in-phase-3-study-in-rheumatoid-arthritis-idUSFWN1RM0N7",
    "ord_in_thread": 0,
    "title": "BRIEF-AbbVie Says Upadacitinib Met All Primary And Ranked Secondary Endpoints In Phase 3 Study In Rheumatoid Arthritis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - AbbVie Inc:\n* UPADACITINIB MEETS ALL PRIMARY AND RANKED SECONDARY ENDPOINTS INCLUDING SUPERIORITY VERSUS ADALIMUMAB IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS\n* ALL RANKED SECONDARY ENDPOINTS ALSO MET IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS\n* PLANS GLOBAL REGULATORY SUBMISSIONS FOR UPADACITINIB IN RHEUMATOID ARTHRITIS IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-09T21:05:00.000+03:00",
    "crawled": "2018-04-10T12:50:52.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "abbvie",
        "inc",
        "upadacitinib",
        "meet",
        "primary",
        "ranked",
        "secondary",
        "endpoint",
        "including",
        "superiority",
        "versus",
        "adalimumab",
        "phase",
        "study",
        "rheumatoid",
        "arthritis",
        "ranked",
        "secondary",
        "endpoint",
        "also",
        "met",
        "phase",
        "study",
        "rheumatoid",
        "arthritis",
        "plan",
        "global",
        "regulatory",
        "submission",
        "upadacitinib",
        "rheumatoid",
        "arthritis",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}